Transforming Women's Gynecologic Health, Starting with Ovarian Cancer.
We believe early detection of ovarian cancer risk is crucial for improving outcomes. Our innovative testing options empower women of all backgrounds to take control of their gynecologic health, regardless of menopausal status. Through data-driven solutions, we support healthcare providers in delivering optimal care.
Our Products
OvaWatch®: A non-invasive blood test for assessing ovarian cancer risk in women with benign or indeterminate adnexal masses demonstrating over 99% negative predictive value.
Ova1Plus®: Ova1* is an FDA-cleared blood test that combines multiple biomarkers to assess the risk of ovarian malignancy in women with adnexal masses planned for surgery with over 96% sensitivity.
COMING SOON
EndoCheck℠ A pioneering non-invasive test to aid in endometrioma identification.
Groundbreaking Gynecologic research
Our research efforts are dedicated to improving women's lives through earlier risk assessment, more accurate diagnoses, and personalized care strategies through rigorous scientific investigation. We combine cutting-edge technology with clinical expertise to develop innovative diagnostic solutions. By continually pushing the boundaries of medical science, we aim to transform the landscape of gynecologic health.
Watch Aspira’s CEO, Nicole Sandford, and Clinical Advisory Board member, Dr. Tamika Sea MD, FACOG, discuss the establishment of Aspira’s Clinical Advisory Board, an element of its overall mission to develop and distribute high-impact diagnostic tools for gynecologic disease with Jane King on New to The Street.
On December 11, 2023, Aspira’s CEO, Nicole Sandford, SVP, Michelle Snider, and Sales Rep. & Patient, Lottie Wilder, were interviewed by Jane King on New to The Street to discuss Aspira’s commercial refresh, what’s ahead for the company, and Lottie's personal health journey.
Most Recent Press Releases
July 01, 2024
Aspira Women’s Health Announces $1.935 Million Private Placement Equity Financing
July 01, 2024 17:24 ET AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited…
June 12, 2024
Aspira Women’s Health Provides Commercial, Reimbursement and Cash Guidance Updates
June 13, 2024 08:00 ET Monthly OvaSuiteSM product volume grew by more than 26% in May compared to January Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite Cash used in operations guidance for 2024 expected to be lowered AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the…
Ready to connect with us?
PRECAUTION:
OVAWATCH IS INTENDED FOR USE AS A NON-INVASIVE TEST TO ASSESS THE RISK OF OVARIAN CANCER FOR WOMEN WITH ADNEXAL MASSES, EVALUATED BY INITIAL CLINICAL ASSESSMENT (ICA) AS INDETERMINATE OR BENIGN. IN CONJUNCTION WITH IMAGING (ULTRASOUND AND/OR CT) AND CLINICAL ASSESSMENT, THIS TEST WILL SUPPORT PHYSICIANS IN MAKING INFORMED CLINICAL DECISIONS IN THE MANAGEMENT OF WOMEN WITH ADNEXAL MASSES. THE TEST IS NOT INTENDED AS A SCREENING TEST OR A STAND-ALONE DIAGNOSTIC ASSAY.
OVA1 AND OVERA SHOULD NOT BE USED WITHOUT AN INDEPENDENT CLINICAL AND IMAGING EVALUATION AND IS NOT INTENDED TO BE A SCREENING TEST OR TO DETERMINE WHETHER A PATIENT SHOULD PROCEED TO SURGERY. INCORRECT USE CARRIES THE RISK OF UNNECESSARY TESTING, SURGERY, AND/OR DELAYED DIAGNOSIS.
*In cases of an intermediate Ova1(r) result, the FDA-cleared Overa(r) reflex is performed to increase specificity